ClinicalTrials.gg
CompletedNCT06130566COAST 1Updated Jul 22, 2026

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

A Phase 3 interventional study of Amlitelimab and Placebo in Dermatitis Atopic, sponsored by Sanofi. Completed at 148 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
601
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
5th of 11
601 · median 589
Started
2023
with 3 others
Phase 3
5 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
9 of 11
Sanofi

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one is the 5th largest by enrollment, is one of 4 that started in 2023, is one of 5 in phase 3, and was the 6th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older.

Study details include:

At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY).

For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up.

For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period.

The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600] (ESTUARY).

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 12 years of age (when signing form)
  • Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
  • Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, and/or inadequate response to systemic therapies (within 12 months before screening)
  • v-IGA-AD of 3 or 4 at baseline visit
  • EASI score of 16 or higher at baseline
  • AD involvement of 10% or more of BSA at baseline
  • Weekly average of daily PP-NRS of ≥ 4 at baseline visit.
  • Able and willing to comply with requested study visits and procedures
  • Body weight ≥25 kg

Exclusion criteria

Exclusion Criteria:

  • Skin co-morbidity that would adversely affect the ability to undertake AD assessments
  • Known history of or suspected significant current
  • Any or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured >5 years prior to baseline)
  • History of solid organ or stem cell transplant
  • Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline (1 week in the event of superficial skin infections)
  • Positive for (HIV), or at screening visit
  • Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
  • Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
  • In the Investigator's opinion, any laboratory results or protocol specified laboratory abnormalities at screening
  • History of or allergy to any of the or medicinal product (IMP)

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
601 participants (actual)

Study arms

  • Experimental
    Amlitelimab dose 1

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Experimental
    Amlitelimab dose 2

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Placebo comparator
    Placebo

    Subcutaneous injection as per protocol

    Drug: Placebo

Interventions

  • Injection solution SC injection

    Also known as: SAR445229

  • DrugPlacebo

    Injection solution SC injection

06

What researchers measure

Primary outcomes

  1. EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Week 24

  2. EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Week 24

  3. US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Week 24

Secondary outcomes

  1. Proportion of participants reaching EASI-75 at Week 24 (for US and US reference countries only)

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.

    Time frame: Week 24

  2. Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) and a reduction from baseline of ≥2 points

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to Week 24

  3. Proportion of participants with ≥4-point reduction in weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) from baseline in participants with baseline weekly average of daily PP-NRS ≥4

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  4. Proportion of participants reaching EASI-75

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.

    Time frame: Baseline to Week 20

  5. Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to Week 20

  6. Proportion of participants reaching EASI-90

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.

    Time frame: Baseline to Week 24

  7. Proportion of participants reaching EASI-100

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.

    Time frame: Baseline to Week 24

  8. Proportion of participants with PP-NRS 0 or 1

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  9. Change in Dermatology Life Quality Index (DLQI) from baseline in participants with age ≥16 years old

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 24

  10. Proportion of participants with a reduction in DLQI ≥4 from baseline in participants with age ≥16 years old and with DLQI baseline ≥4

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 24

  11. Change in Children Dermatology Life Quality Index (CDLQI) from baseline in participants with age ≥12 to <16 years old

    The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 24

  12. Proportion of participants with a reduction in CDLQI ≥6 from baseline in participants with age ≥12 to <16 years old and with CDLQI baseline ≥6

    The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 24

  13. Change in Hospital Anxiety Depression Scale (HADS) from baseline

    The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

    Time frame: Baseline to Week 24

  14. Proportion of participants with HADS subscale Anxiety (HADS-A) <8 in participants with baseline HADS-A ≥8

    HADS-A score ranges 0-21 with higher score indicating a poorer state.

    Time frame: Baseline to Week 24

  15. Proportion of participants with HADS subscale Depression (HADS-D) <8 in participants with HADS-D baseline ≥8

    HADS-D score ranges 0-21 with higher score indicating a poorer state.

    Time frame: Baseline to Week 24

  16. Absolute change in weekly average of daily Skin Pain-Numerical Rating Scale (SP-NRS) from baseline

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to Week 24

  17. Proportion of participants with a reduction in weekly average of daily SP-NRS ≥4 from baseline in participants with baseline weekly average of daily SP-NRS ≥4

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to Week 24

  18. Percent change in weekly average of daily SP-NRS from baseline

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to Week 24

  19. Proportion of participants with vIGA-AD 0

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Week 24

  20. Absolute change in weekly average of daily Sleep Disturbance-Numerical Rating Scale (SD-NRS) from baseline

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.

    Time frame: Baseline to Week 24

  21. Proportion of participants with a reduction in weekly average of daily SD-NRS ≥3 from baseline in participants with Baseline weekly average of daily SD-NRS ≥3

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.

    Time frame: Baseline to Week 24

  22. Percent change in weekly average of daily SD-NRS

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.

    Time frame: Baseline to Week 24

  23. Percent change in EASI score from baseline

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Baseline to Week 24

  24. Percent change in weekly average of daily PP-NRS from baseline

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  25. Absolute change in weekly average of daily PP-NRS from baseline

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  26. Proportion of participants reaching EASI-50

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.

    Time frame: Baseline to Week 24

  27. Proportion of participants with EASI ≤7

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Baseline to Week 24

  28. Change in percent Body Surface Area (BSA) affected by AD from baseline

    Time frame: Baseline to Week 24

  29. Percent change in Scoring Atopic Dermatitis (SCORAD) index from baseline

    The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 24

  30. Absolute change in SCORAD index from baseline

    The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 24

  31. Proportion of participants with a reduction in SCORAD ≥ 8.7 points from baseline in participants with baseline SCORAD score ≥ 8.7

    The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 24

  32. Change in Patient Oriented Eczema Measure (POEM) from baseline

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline to Week 24

  33. Proportion of participants with a reduction in POEM ≥4 from baseline in participants with POEM Baseline ≥4

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline to Week 24

  34. Proportion of participants with rescue medication use

    Time frame: Baseline to Week 24

  35. Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs), experienced Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI)

    Time frame: Baseline to Week 40

  36. Serum amlitelimab concentrations

    Time frame: Baseline to Week 40

  37. Incidence of antidrug antibodies (ADAs) of amlitelimab

    Time frame: Baseline to Week 40

07

Study locations

148 sites
  • Scottsdale Clinical Trials- Site Number : 8401149
    Scottsdale, Arizona 85260, United States
  • First OC Dermatology- Site Number : 8401025
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research- Site Number : 8401018
    Fremont, California 94538, United States
  • Sunwise Clinical Research- Site Number : 8401022
    Lafayette, California 94549, United States
  • Carbon Health - North Hollywood - NoHo West- Site Number : 8401218
    North Hollywood, California 91606, United States
  • Northridge Clinical Trials - Northridge- Site Number : 8401080
    Northridge, California 91325, United States
  • St Jude Clinical Research- Site Number : 8401287
    Doral, Florida 33172, United States
  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286
    Fort Myers, Florida 33919, United States
  • Direct Helpers Research Center- Site Number : 8401056
    Hialeah, Florida 33012, United States
  • Encore Medical Research- Site Number : 8401030
    Hollywood, Florida 33021, United States
  • Florida International Research Center- Site Number : 8401091
    Miami, Florida 33173, United States
  • Miami Dermatology and Laser Research- Site Number : 8401086
    Miami, Florida 33173, United States
  • Clinical Neuroscience Solutions - Orlando - South Delaney Avenue- Site Number : 8401035
    Orlando, Florida 32806, United States
  • Cleaver Medical Group Dermatology- Site Number : 8401139
    Cumming, Georgia 30040, United States
  • Skin Care Physicians of Georgia - Macon- Site Number : 8401034
    Macon, Georgia 31217, United States
  • Javara Research - Thomasville- Site Number : 8401189
    Thomasville, Georgia 31792, United States
  • Rophe Adult & Pediatric Medicine- Site Number : 8401289
    Union City, Georgia 30291, United States
  • Skin Sciences- Site Number : 8401039
    Louisville, Kentucky 40217, United States
  • MedPharmics - Covington- Site Number : 8401137
    Covington, Louisiana 70433, United States
  • MedPharmics - Lafeyette- Site Number : 8401152
    Lafayette, Louisiana 70508, United States
  • Massachusetts General Hospital- Site Number : 8401192
    Boston, Massachusetts 02114, United States
  • Metro Boston Clinical Partners- Site Number : 8401128
    Needham, Massachusetts 02492, United States
  • Revival Research - Doral- Site Number : 8401012
    Dearborn, Michigan 33122, United States
  • Henry Ford Hospital- Site Number : 8401044
    Detroit, Michigan 48202, United States
  • SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058
    Ridgeland, Mississippi 39157, United States
  • MediSearch Clinical Trials- Site Number : 8401140
    Saint Joseph, Missouri 64506, United States
  • Somnos Clinical Research- Site Number : 8401203
    Lincoln, Nebraska 68510, United States
  • Universal Dermatology- Site Number : 8401224
    Fairport, New York 14450, United States
  • Sadick Research Group - New York - Park Avenue- Site Number : 8401050
    New York, New York 10075, United States
  • CHEAR Center- Site Number : 8401123
    The Bronx, New York 10459, United States
  • Onsite Clinical Solutions - Charlotte - Blakeney Park Drive- Site Number : 8401124
    Charlotte, North Carolina 28277, United States
  • Oregon Medical Research Center- Site Number : 8401017
    Portland, Oregon 97201, United States
  • Vial Health - DermDox Dermatology- Site Number : 8401031
    Camp Hill, Pennsylvania 17011, United States
  • Paddington Testing Company- Site Number : 8401041
    Philadelphia, Pennsylvania 19103, United States
  • Clinical Research of Philadelphia- Site Number : 8401193
    Philadelphia, Pennsylvania 19114, United States
  • Tribe Clinical Research - 525 Verdae Boulevard- Site Number : 8401225
    Greenville, South Carolina 29607, United States
  • Dermatology Treatment and Research Center- Site Number : 8401164
    Dallas, Texas 75230, United States
  • Skin Specialist of Addison- Site Number : 8401208
    Dallas, Texas 75254, United States
  • Texas Dermatology and Laser Specialists- Site Number : 8401131
    San Antonio, Texas 78218, United States
  • Stryde Research - Epiphany Dermatology- Site Number : 8401185
    Southlake, Texas 76092, United States
  • Springville Dermatology - Springville- Site Number : 8401106
    Springville, Utah 84663, United States
  • Virginia Dermatology & Skin Cancer Center- Site Number : 8401047
    Norfolk, Virginia 23502, United States
  • Investigational Site Number : 0320023
    Buenos Aires, Buenos Aires F.D. 1028, Argentina
  • Investigational Site Number : 0320024
    SAN Miguel de Tucumã¡n, Tucumán Province T4000, Argentina
  • Investigational Site Number : 0320022
    Buenos Aires, 1012, Argentina
  • Investigational Site Number : 0320010
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0360010
    Westmead, New South Wales 2145, Australia
  • Investigational Site Number : 0360007
    Woolloongabba, Queensland 4102, Australia
  • Investigational Site Number : 0360008
    Melbourne, Victoria 3002, Australia
  • Investigational Site Number : 0360006
    Melbourne, Victoria 3004, Australia
  • Investigational Site Number : 0361006
    Traralgon, Victoria 3844, Australia
  • Centro de Pesquisas da Clínica IBIS- Site Number : 0760002
    Salvador, Estado de Bahia 41820-020, Brazil
  • Hospital São Domingos- Site Number : 0760028
    Bequimão, Maranhão 65060-645, Brazil
  • Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760022
    Curitiba, Paraná 80060-900, Brazil
  • PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR- Site Number : 0760023
    Curitiba, Paraná 80230-130, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Clinica de Alergia Martti Antila- Site Number : 0760006
    Sorocaba, São Paulo 18040-425, Brazil
  • CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760018
    Rio de Janeiro, 22241-180, Brazil
  • Faculdade de Medicina do ABC- Site Number : 0760001
    Santo André, 09060-650, Brazil
  • Centro de Desenvolvimento em Estudos ClÌnicos Brasil- Site Number : 0760014
    São Paulo, 04020-060, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760012
    São Paulo, 05403-000, Brazil
  • Investigational Site Number : 1240031
    Edmonton, Alberta T5K 2V4, Canada
  • Investigational Site Number : 1240040
    Surrey, British Columbia V3R 6A7, Canada
  • Investigational Site Number : 1240033
    Ajax, Ontario L1S 7K8, Canada
  • Investigational Site Number : 1240055
    Hamilton, Ontario L8S 1G5, Canada
  • Investigational Site Number : 1240029
    London, Ontario N6A 2C2, Canada
  • Investigational Site Number : 1241108
    Niagara Falls, Ontario L2H 1H5, Canada
  • Investigational Site Number : 1240034
    Ottawa, Ontario K1H 7X8, Canada
  • Investigational Site Number : 1240013
    Toronto, Ontario M3B 3N1, Canada
  • Investigational Site Number : 1240035
    Toronto, Ontario M5A 3R6, Canada
  • Investigational Site Number : 1240043
    Saint-Jérôme, Quebec J7Z 7E2, Canada
  • Investigational Site Number : 1240028
    Regina, Saskatchewan S4V 1R9, Canada
  • Investigational Site Number : 1240036
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Investigational Site Number : 1520009
    Osorno, Reg Metropolitana de Santiago 5311523, Chile
  • Investigational Site Number : 1520008
    Santiago, Reg Metropolitana de Santiago 7500587, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520010
    Santiago, Reg Metropolitana de Santiago 8330034, Chile
  • Investigational Site Number : 1520011
    Santiago, Reg Metropolitana de Santiago 8380456, Chile
  • Investigational Site Number : 1520005
    Santiago, Reg Metropolitana de Santiago 8380465, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
  • Investigational Site Number : 1520006
    Viña del Mar, Valparaiso 2530900, Chile
  • Investigational Site Number : 1520012
    Talcahuano, 2687000, Chile
  • Investigational Site Number : 1560042
    Beijing, 100034, China
  • Investigational Site Number : 1560060
    Chengdu, 610072, China
  • Investigational Site Number : 1560068
    Chengdu, 610091, China
  • Investigational Site Number : 1560057
    Chongqing, 400016, China
  • Investigational Site Number : 1560065
    Chongqing, 400065, China
  • Investigational Site Number : 1560058
    Guangzhou, 510630, China
  • Investigational Site Number : 1560059
    Jinan, 250014, China
  • Investigational Site Number : 1560064
    Shenzhen, 518026, China
  • Investigational Site Number : 2500008
    Antony, 92160, France
  • Investigational Site Number : 2500009
    Nantes, 44093, France
  • Investigational Site Number : 2500003
    Paris, 75010, France
  • Investigational Site Number : 2500007
    Reims, 51100, France
  • Investigational Site Number : 2500010
    Romans-sur-Isère, 26102, France
  • Investigational Site Number : 2760009
    Bad Bentheim, 48455, Germany
  • Investigational Site Number : 2760014
    Buxtehude, 21614, Germany
  • Investigational Site Number : 2760017
    Hamburg, 20095, Germany
  • Investigational Site Number : 2762208
    Kiel, 24105, Germany

Showing the first 100 of 148 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2025, 20 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Nov 14, 2023
StartActual
Nov 8, 2023
Primary completionActual
Jul 23, 2025
CompletionActual
Nov 13, 2025
Results delay requested
Jul 20, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06130566
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Nov 8, 2023
Primary completion
Jul 23, 2025
Completion
Nov 13, 2025
Last update
Jul 22, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion